http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 24 Aug 2026 02:00:51 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO), a biotechnology company focused on RNA therapeutics, has signed a definitive share purchase agreement to acquire 100% of Etherna Immunotherapies NV at an enterprise value of €30 million, according to a press release from the company.</p> <p>The acquisition will be funded through a combination of cash and a share consideration. To finance the cash portion, Valerio priced a €40.25 million private investment in public equity (PIPE) offering, issuing 68,220,333 new ordinary shares at €0.59 per share, representing a 25% discount to the three-day volume-weighted average price prior to pricing.</p> <p>Existing shareholders Artal International SCA, Financière de http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html Mon, 24 Aug 2026 02:00:51 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO), a biotechnology company focused on RNA therapeutics, has signed a definitive share purchase agreement to acquire 100% of Etherna Immunotherapies NV at an enterprise value of €30 million, according to a press release from the company.</p> <p>The acquisition will be funded through a combination of cash and a share consideration. To finance the cash portion, Valerio priced a €40.25 million private investment in public equity (PIPE) offering, issuing 68,220,333 new ordinary shares at €0.59 per share, representing a 25% discount to the three-day volume-weighted average price prior to pricing.</p> <p>Existing shareholders Artal International SCA, Financière de http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html Mon, 24 Aug 2026 02:00:51 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO), a biotechnology company focused on RNA therapeutics, has signed a definitive share purchase agreement to acquire 100% of Etherna Immunotherapies NV at an enterprise value of €30 million, according to a press release from the company.</p> <p>The acquisition will be funded through a combination of cash and a share consideration. To finance the cash portion, Valerio priced a €40.25 million private investment in public equity (PIPE) offering, issuing 68,220,333 new ordinary shares at €0.59 per share, representing a 25% discount to the three-day volume-weighted average price prior to pricing.</p> <p>Existing shareholders Artal International SCA, Financière de http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html Mon, 24 Aug 2026 02:00:51 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO), a biotechnology company focused on RNA therapeutics, has signed a definitive share purchase agreement to acquire 100% of Etherna Immunotherapies NV at an enterprise value of €30 million, according to a press release from the company.</p> <p>The acquisition will be funded through a combination of cash and a share consideration. To finance the cash portion, Valerio priced a €40.25 million private investment in public equity (PIPE) offering, issuing 68,220,333 new ordinary shares at €0.59 per share, representing a 25% discount to the three-day volume-weighted average price prior to pricing.</p> <p>Existing shareholders Artal International SCA, Financière de http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html Mon, 24 Aug 2026 02:00:51 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO), a biotechnology company focused on RNA therapeutics, has signed a definitive share purchase agreement to acquire 100% of Etherna Immunotherapies NV at an enterprise value of €30 million, according to a press release from the company.</p> <p>The acquisition will be funded through a combination of cash and a share consideration. To finance the cash portion, Valerio priced a €40.25 million private investment in public equity (PIPE) offering, issuing 68,220,333 new ordinary shares at €0.59 per share, representing a 25% discount to the three-day volume-weighted average price prior to pricing.</p> <p>Existing shareholders Artal International SCA, Financière de http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html Mon, 24 Aug 2026 02:00:51 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO), a biotechnology company focused on RNA therapeutics, has signed a definitive share purchase agreement to acquire 100% of Etherna Immunotherapies NV at an enterprise value of €30 million, according to a press release from the company.</p> <p>The acquisition will be funded through a combination of cash and a share consideration. To finance the cash portion, Valerio priced a €40.25 million private investment in public equity (PIPE) offering, issuing 68,220,333 new ordinary shares at €0.59 per share, representing a 25% discount to the three-day volume-weighted average price prior to pricing.</p> <p>Existing shareholders Artal International SCA, Financière de http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html Mon, 24 Aug 2026 02:00:51 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO), a biotechnology company focused on RNA therapeutics, has signed a definitive share purchase agreement to acquire 100% of Etherna Immunotherapies NV at an enterprise value of €30 million, according to a press release from the company.</p> <p>The acquisition will be funded through a combination of cash and a share consideration. To finance the cash portion, Valerio priced a €40.25 million private investment in public equity (PIPE) offering, issuing 68,220,333 new ordinary shares at €0.59 per share, representing a 25% discount to the three-day volume-weighted average price prior to pricing.</p> <p>Existing shareholders Artal International SCA, Financière de http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html Mon, 24 Aug 2026 02:00:51 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO), a biotechnology company focused on RNA therapeutics, has signed a definitive share purchase agreement to acquire 100% of Etherna Immunotherapies NV at an enterprise value of €30 million, according to a press release from the company.</p> <p>The acquisition will be funded through a combination of cash and a share consideration. To finance the cash portion, Valerio priced a €40.25 million private investment in public equity (PIPE) offering, issuing 68,220,333 new ordinary shares at €0.59 per share, representing a 25% discount to the three-day volume-weighted average price prior to pricing.</p> <p>Existing shareholders Artal International SCA, Financière de http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html Mon, 24 Aug 2026 02:00:51 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html <p>Valerio Therapeutics (Euronext Growth Paris: ALVIO), a biotechnology company focused on RNA therapeutics, has signed a definitive share purchase agreement to acquire 100% of Etherna Immunotherapies NV at an enterprise value of €30 million, according to a press release from the company.</p> <p>The acquisition will be funded through a combination of cash and a share consideration. To finance the cash portion, Valerio priced a €40.25 million private investment in public equity (PIPE) offering, issuing 68,220,333 new ordinary shares at €0.59 per share, representing a 25% discount to the three-day volume-weighted average price prior to pricing.</p> <p>Existing shareholders Artal International SCA, Financière de http://www.streetinsider.com/Mergers+and+Acquisitions/Valerio+Therapeutics+to+acquire+Etherna+in+%E2%82%AC30M+deal+with+PIPE+financing/26963328.html Mon, 24 Aug 2026 02:00:51 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Press+Releases/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568 http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html <ul class="bwlistdisc"> <li> Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV (&quot;<b>Etherna</b>&quot;), and the related contribution agreement, based on an enterprise value of €30 million, to be settled through a combination of a cash consideration and a share consideration (the &quot;<b>Contributions</b>&quot;) <br></br> <br></br> </li> <li> €40.25 million PIPE financing successfully priced with support from new and existing investors, to finance the cash consideration of the Acquisition and support the development of the combined company <br></br> <br></br> </li> <li> Shareholder approval of the Contributions, at an extraordinary general meeting to be convened for that purpose, with approval already secured through irrevocable voting undertakings from existing shareholders representing http://www.streetinsider.com/Business+Wire/Valerio+Therapeutics+Announces+Signing+of+Definitive+Agreements+for+the+Acquisition+of+Etherna+Immunotherapies%2C+Building+a+Leading+Platform+in+Targeted+RNA%2C+and+%E2%82%AC40.25+Million+PIPE+Financing+From+Ne/26963327.html Mon, 24 Aug 2026 02:00:00 -0400 A.01025616 A.07298218 A.17839596 ALONX ALVIO O.00046810 O.00200415 O.00367392 O.15112568